Search clinical trials for: RSV_PreF3 Vaccine (GSK3844766A) adjuvanted with AS01B

Total 76 results

GlaxoSmithKline

Completed

A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults

Respiratory Syncytial Virus Infections

United States, Belgium
GlaxoSmithKline

Completed

A Study to Test GlaxoSmithKline's (GSK) Respiratory Syncytial Virus RSV Candidate Vaccine's Safety and Immune Response in Japanese Older Adults

Respiratory Syncytial Virus Infections

Japan
GlaxoSmithKline

Completed

Safety Study of Four Candidate Influenza Vaccines to Prevent Influenza Disease in the Elderly Population

Influenza

Belgium
GlaxoSmithKline

Completed

Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 OA Investigational Vaccine in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study

Respiratory Syncytial Virus Infections

United States, Belgium
U.S. Army Medical Research and Development Command
GlaxoSmithKline; United States Agency for International Development (USAID); Walter... and other collaborators

Completed

Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) to Evaluate the Safety and Efficacy of the Plasmodium Falciparum Vaccine Candidate FMP012 Administered Intramuscularly With AS01B Adjuvant System in Healthy Malaria-Naïve Adults

Malaria

United States
U.S. Army Medical Research and Development Command
GlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR)

Completed

A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults (in Puerto Rico) (DPIV-002)

Dengue Fever

Puerto Rico
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of GSK's Clostridium Difficile Vaccine 2904545A When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years

Clostridium Infections

Belgium
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults

HIV Infections

United States, South Africa
GlaxoSmithKline

Recruiting

A Study on the Safety and Immune Response of AS37 Together With Hepatitis B Antigen in Adults Aged 18-45 Years

Hepatitis B

Germany, United Kingdom, Belgium
Bill & Melinda Gates Medical Research Institute
Iqvia Pty Ltd

Withdrawn

Proof of Concept Trial of Adjuvant Activity of SWE, a Squalene-based -Oil-in-water Emulsion

Influenza
U.S. Army Medical Research and Development Command
GlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR)

Completed

Safety and Efficacy Study of RTS,S AS02A/AS01B Vaccine to Prevent Malaria

Malaria

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.

Malaria | Malaria Vaccines

Ghana
U.S. Army Medical Research and Development Command
GlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR); The PATH Malaria...

Completed

Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America

Plasmodium Falciparum Malaria

United States
Novartis
Novartis Vaccines

Completed

Safety, Tolerability, Immunogenicity And CPG Dosage Finding Study of Novartis CpG Adjuvanted Flu Vaccine

Influenza Infection

Switzerland
Sinovac Biotech Co., Ltd

Completed

Safety and Immunogenicity of an Inactivated EV71 Vaccine in Infants

Infection, Viral, Enterovirus

China
GlaxoSmithKline

Completed

Study to Assess the Immunogenicity and Safety of GSK's Investigational Vaccine (GSK3277511A) When Given to Healthy Smokers and Ex-smokers After Administration of Shingrix Vaccine

Respiratory Disorders

France, Estonia, Spain, Finland, Italy
Novavax

Completed

Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine

Covid19 | SARS-CoV Infection

Australia
Novavax
PATH

Completed

RSV-F Vaccine Dose Ranging Study in Young Women

Respiratory Syncytial Virus (RSV)

United States
DynPort Vaccine Company LLC, A GDIT Company

Completed

Randomized Single-Blinded Study to Evaluate Safety and Immunogenicity of Recombinant Plague Vaccine With and Without Adjuvant

Plague Vaccine

United States
Colby Pharmaceutical Company

Completed

Safety and Efficacy Study of Fluzone® Vaccine Combined With Different Doses of JVRS-100 Adjuvant (H-100-001)

Influenza

United States
Medigen Vaccine Biologics Corp.

Completed

A Study to Evaluate the Safety and Immunogenicity of H7N9 Influenza Vaccine (AT-501) in Healthy Adult Subjects

H7N9 Influenza Vaccine

Taiwan
U.S. Army Medical Research and Development Command
GlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR)

Withdrawn

TDENV PIV and LAV Dengue Prime-boost Strategy Using AS03B Adjuvant

Dengue

United States
GlaxoSmithKline

Completed

Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in HIV-positive Adults.

Tuberculosis

Switzerland
GlaxoSmithKline

Completed

Safety and Immunogenicity of 2 Formulations of Tuberculosis Vaccine GSK692342 Given at 0,1 Months to Healthy Adults

Tuberculosis

Belgium
Yisheng Biopharma (Singapore) Pte. Ltd.
Duke-NUS Graduate Medical School

Completed

Safety and Efficacy of a PIKA Rabies Vaccine Containing the PIKA Adjuvant

Rabies

Singapore
Madhu Chhanda Choudhary
National Institute of Allergy and Infectious Diseases (NIAID)

Recruiting

Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy (NETI)

HIV Infections

United States
PX'Therapeutics
European Commission

Completed

Safety & Immunogenicity of Immunisations With EN41-UGR7C HIV Vaccine

- HIV

United Kingdom
Sinovac Biotech Co., Ltd

Withdrawn

Safety and Immunogenicity of EV71 Vaccine With or Without Aluminum Adjuvant in Infants

Infection, Viral, Enterovirus

China
U.S. Army Medical Research and Development Command
GlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR)

Completed

Study of Varying Injection Schedules of TDENV-PIV Vaccine With AS03B Adjuvant and Placebo in Healthy US Adults

Dengue

United States
Nova Immunotherapeutics Limited
The Emmes Company, LLC; Nova Laboratories Limited; Mercia Pharma Inc.

Unknown

The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101) (MER4101)

Influenza, Human

United States
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of GSK Biologicals Tuberculosis Vaccines (692342) to Healthy Adults

Tuberculosis

Philippines
Yisheng Biopharma (Singapore) Pte. Ltd.

Completed

Efficacy and Safety of a PIKA Rabies Vaccine Containing the PIKA Adjuvant With an Accelerated Regimen

Rabies

Singapore
University of Oxford
European and Developing Countries Clinical Trials Partnership (EDCTP); Institut...

Completed

Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso

Malaria,Falciparum

Burkina Faso
International Vaccine Institute
Massachusetts General Hospital; EuBiologics Co.,Ltd

Recruiting

Dose Escalation Study to Evaluate the Safety and Immunogenicity of the Cholera Conjugate Vaccine in Healthy Adults

Cholera Vaccination Reaction

Korea, Republic of
Novavax

Completed

Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1™ Adjuvants In Clinically-Stable Older Adults

Respiratory Syncytial Viruses

Australia
Institut Pasteur
Wellcome Trust; Walter Reed Army Institute of Research (WRAIR); Parexel; Bill &... and other collaborators

Completed

A Study to Investigate the Safety and Immunogenicity of the SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine Against Shigella Flexneri 2a (GlycoShig3)

Healthy

Kenya
Pfizer

Completed

A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 To 85 Years, Who Will Each Receive 3 Doses Of Vaccine.

Clostridium Difficile

United States, Canada
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Effectiveness of an Adjuvant in Improving Immune Response to Hepatitis B Virus Vaccine in HIV Infected Individuals

HIV Infections

United States
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two(Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines in Non-Elderly Adult and Elderly Subjects

Pandemic Influenza Disease

Italy
NovaDigm Therapeutics, Inc.
United States Department of Defense

Completed

Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine

Candidiasis | Staphylococcal Infections | Yeast Infections

United States
Novavax

Completed

A Phase I Randomized, Observer-Blinded, Dose-Ranging Study in Healthy Subjects 24 to <72 Months of Age

Respiratory Synctial Virus

Canada
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Clostridium Difficile Toxoid Vaccine (ACAM-CDIFF™) in Subjects With Clostridium Difficile Infection

Diarrhea | Clostridium Difficile Infection

United Kingdom, United States
University of Oxford

Recruiting

A Study to Test Experimental Blood Stage Malaria Vaccine in Burkina Faso.

Malaria,Falciparum

Burkina Faso
The University of Hong Kong

Completed

Intra-dermal With Topical Imiquimod Pretreatment Versus Intra-muscular Hepatitis B Vaccination in IBD Patients

Hepatitis B | Inflammatory Bowel Diseases

China
Sanofi

Completed

A Study of Different Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly

Influenza | Swine-origin A/H1N1 Influenza

United States
University of Wisconsin, Madison

Completed

HepB-CpG Series for Healthcare Workers Who Are Hepatitis B Vaccine Nonresponders

Healthcare Worker, Hepatitis B Vaccine, Nonresponder

United States
Novavax
Bill and Melinda Gates Foundation

Completed

A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization

Respiratory Syncytial Virus Infections

United States, Argentina, Australia, Bangladesh, Chile, Mexico, New Zealand, Philippines, South Africa, Spain, United Kingdom
Novavax

Completed

A Study to Evaluate Safety and Immunogenicity of a COVID-19 Vaccine in People Living With HIV at Risk for SARS-CoV-2 (COVID-19) (COVID-19)

SARS-CoV-2 Infection

South Africa
HepNet Study House, German Liverfoundation

Terminated

H1N1sw Vaccine in Adult Transplant Recipients

Immunocompromised

Germany

3

Subscribe